Literature DB >> 27457074

A cyclin D1-negative mantle cell lymphoma with an IGL-CCND2 translocation that relapsed with blastoid morphology and aggressive clinical behavior.

Daisuke Kurita1,2, Kengo Takeuchi3, Sumiko Kobayashi4, Atsuko Hojo4,5, Yoshihito Uchino4, Masashi Sakagami4, Shimon Ohtake4, Hiromichi Takahashi4, Katsuhiro Miura4, Noriyoshi Iriyama4, Masahiko Sugitani6, Hiroaki Miyoshi7, Yoshihiro Hatta8, Koichi Ohshima7, Masami Takei4.   

Abstract

Mantle cell lymphoma (MCL) is a B cell neoplasm characterized by cyclin D1 overexpression; its prognosis is poor, especially when it exhibits a blastoid morphology. Cyclin D1-negative MCL is rare, and its pathogenesis and progression remain unclear. Herein, we describe a cyclin D1-negative, cyclin D2-positive MCL with a CCND2 and immunoglobulin lambda light chain (IGL) translocation. The patient was initially diagnosed with cyclin D1-negative MCL and achieved complete remission via combination chemotherapy and autologous stem cell transplantation. After relapsing, he was diagnosed with a blastoid variant of MCL that showed lymphoid cells with dispersed chromatin and more mitotic figures and higher p53 expression compared with the initial MCL. Despite salvage therapies, the disease became refractory, and the patient died 28 months after initiating chemotherapy. This case demonstrates that blastoid morphology in cyclin D1-negative MCL with IGL-CCND2 translocation indicates progression to a more aggressive neoplasm, similar to cyclin D1-positive MCL.

Entities:  

Keywords:  CCND2 gene translocation; Cyclin D1; Cyclin D2; Mantle cell lymphoma; SOX11

Mesh:

Substances:

Year:  2016        PMID: 27457074     DOI: 10.1007/s00428-016-1995-9

Source DB:  PubMed          Journal:  Virchows Arch        ISSN: 0945-6317            Impact factor:   4.064


  17 in total

1.  The impact of cyclin D1 mRNA isoforms, morphology and p53 in mantle cell lymphoma: p53 alterations and blastoid morphology are strong predictors of a high proliferation index.

Authors:  Julia Slotta-Huspenina; Ina Koch; Laurence de Leval; Gisela Keller; Margit Klier; Karin Bink; Marcus Kremer; Mark Raffeld; Falko Fend; Leticia Quintanilla-Martinez
Journal:  Haematologica       Date:  2012-02-07       Impact factor: 9.941

2.  Assessment of SOX11 expression in routine lymphoma tissue sections: characterization of new monoclonal antibodies for diagnosis of mantle cell lymphoma.

Authors:  Davide Soldini; Alexandra Valera; Carla Solé; Jara Palomero; Virginia Amador; José Ignacio Martin-Subero; Inmaculada Ribera-Cortada; Cristina Royo; Itziar Salaverria; Sílvia Beà; Elena Gonzalvo; Henrik Johannesson; Mileyka Herrera; Lluís Colomo; Antonio Martinez; Elias Campo
Journal:  Am J Surg Pathol       Date:  2014-01       Impact factor: 6.394

3.  Gain of 3q and deletion of 11q22 are frequent aberrations in mantle cell lymphoma.

Authors:  O Monni; R Oinonen; E Elonen; K Franssila; L Teerenhovi; H Joensuu; S Knuutila
Journal:  Genes Chromosomes Cancer       Date:  1998-04       Impact factor: 5.006

4.  Mantle cell lymphoma: a clinicopathologic study of 80 cases.

Authors:  L H Argatoff; J M Connors; R J Klasa; D E Horsman; R D Gascoyne
Journal:  Blood       Date:  1997-03-15       Impact factor: 22.113

5.  SOX11 expression is highly specific for mantle cell lymphoma and identifies the cyclin D1-negative subtype.

Authors:  Ana Mozos; Cristina Royo; Elena Hartmann; Daphne De Jong; Cristina Baró; Alexandra Valera; Kai Fu; Dennis D Weisenburger; Jan Delabie; Shih-Sung Chuang; Elaine S Jaffe; Carmen Ruiz-Marcellan; Sandeep Dave; Lisa Rimsza; Rita Braziel; Randy D Gascoyne; Francisco Solé; Armando López-Guillermo; Dolors Colomer; Louis M Staudt; Andreas Rosenwald; German Ott; Pedro Jares; Elias Campo
Journal:  Haematologica       Date:  2009-11       Impact factor: 9.941

Review 6.  Mantle cell lymphoma--a spectrum from indolent to aggressive disease.

Authors:  Birgitta Sander; Leticia Quintanilla-Martinez; German Ott; Luc Xerri; Isinsu Kuzu; John K C Chan; Steven H Swerdlow; Elias Campo
Journal:  Virchows Arch       Date:  2015-08-23       Impact factor: 4.064

7.  Dose-intensified CHOP with rituximab (R-Double-CHOP) followed by consolidation high-dose chemotherapies for patients with advanced diffuse large B-cell lymphoma.

Authors:  Daisuke Kurita; Katsuhiro Miura; Masaru Nakagawa; Shimon Ohtake; Masashi Sakagami; Yoshihito Uchino; Hiromichi Takahashi; Satomi Kiso; Atsuko Hojo; Hitomi Kodaira; Mai Yagi; Yukio Hirabayashi; Yujin Kobayashi; Noriyoshi Iriyama; Sumiko Kobayashi; Yoshihiro Hatta; Yoshimasa Kura; Masahiko Sugitani; Masami Takei
Journal:  Int J Hematol       Date:  2015-03-17       Impact factor: 2.490

Review 8.  Advances in the understanding of mantle cell lymphoma.

Authors:  Pedro Jares; Elías Campo
Journal:  Br J Haematol       Date:  2008-04-10       Impact factor: 6.998

9.  p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas.

Authors:  L Hernandez; T Fest; M Cazorla; J Teruya-Feldstein; F Bosch; M A Peinado; M A Piris; E Montserrat; A Cardesa; E S Jaffe; E Campo; M Raffeld
Journal:  Blood       Date:  1996-04-15       Impact factor: 22.113

10.  RET, ROS1 and ALK fusions in lung cancer.

Authors:  Kengo Takeuchi; Manabu Soda; Yuki Togashi; Ritsuro Suzuki; Seiji Sakata; Satoko Hatano; Reimi Asaka; Wakako Hamanaka; Hironori Ninomiya; Hirofumi Uehara; Young Lim Choi; Yukitoshi Satoh; Sakae Okumura; Ken Nakagawa; Hiroyuki Mano; Yuichi Ishikawa
Journal:  Nat Med       Date:  2012-02-12       Impact factor: 53.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.